Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial

Author： Gomella L.G.   Liberman S.N.   Mulholland S.G.   Petersen R.O.   Hyslop T.   Corn B.W.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.47, Iss.6, 1996-06, pp. : 870-877

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

By Zietman A.L.   Dallow K.C.   McManus P.A.   Heney N.M.   Shipley W.U.  

Urology, Vol. 47, Iss. 2, 1996-02 ,pp. : 236-239

Elsevier

Access to resources Recommend Favorite

Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy

By Cookson M.S.   Fleshner N.E.   Soloway S.M.   Fair W.R.  

Urology, Vol. 49, Iss. 6, 1997-06 ,pp. : 887-893

Elsevier

Access to resources Recommend Favorite

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

By Wright G.L.   Grob M.   Haley C.   Grossman K.   Newhall K.   Petrylak D.   Troyer J.   Konchuba A.   Schellhammer P.F.   Moriarty R.  

Urology, Vol. 48, Iss. 2, 1996-08 ,pp. : 326-334

Elsevier

Access to resources Recommend Favorite

Informed consent for prostate-specific antigen-based screening

By Brawley O.W.  

Urology, Vol. 61, Iss. 1, 2003-01 ,pp. : 10-12

Elsevier

Access to resources Recommend Favorite

Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome

By Zagars G.K.   Pollack A.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 476-483

Elsevier

Access to resources Recommend Favorite